Quarterly EsoGuard® test
volume increased 31 percent sequentially
NEW
YORK, July 23, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the
"Company"), a commercial-stage, cancer prevention medical
diagnostics company, and majority-owned subsidiary of PAVmed Inc.
(Nasdaq: PAVM), today announced that it performed a record number
of commercial EsoGuard® Esophageal DNA tests in the
second quarter of 2024. The 3,174 tests represent a 31% increase
sequentially from the first quarter.
"Our commercial and clinical teams remain relentlessly focused
on expanding awareness of, demand for and access to EsoGuard
esophageal precancer testing at physician offices, integrated
health systems and #CheckYourFoodTube testing events," said
Lishan Aklog, M.D., Lucid's Chairman
and Chief Executive Officer.
Lucid expects to report full results for the three months ended
June 30, 2024 in mid-August 2024.
Lucid also reported that it held a productive meeting with CMS
Medicare Administrative Contractor (MAC) Palmetto GBA's Molecular
Diagnostics Program (MolDX). Lucid executives joined MolDX
leadership in-person. Also participating were Lucid Vice-Chairman,
Stanley Lapidus, and Sachin Wani, M.D., Professor of Gastroenterology
at the University of Colorado School of
Medicine and a co-author of both the American College of
Gastroenterology (ACG) guideline for Diagnosis and Management of
Barrett's Esophagus, and the American Gastroenterological
Association (AGA) Clinical Practice Update.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company,
and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on
the millions of patients with gastroesophageal reflux disease
(GERD), also known as chronic heartburn, who are at risk of
developing esophageal precancer and cancer. Lucid's
EsoGuard® Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its
EsoCheck® Esophageal Cell Collection Device - the first
and only commercially available tools designed with the goal of
preventing cancer and cancer deaths through widespread, early
detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more
information about its parent company PAVmed, please visit
www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements
that involve risk and uncertainties. Forward-looking statements are
any statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of Lucid Diagnostics' management, are subject to risks
and uncertainties, which could cause actual results to differ from
the forward-looking statements. Risks and uncertainties that may
cause such differences include, among other things, volatility in
the price of Lucid Diagnostics' common stock; general economic and
market conditions; the uncertainties inherent in research and
development, including the cost and time required to advance Lucid
Diagnostics' products to regulatory submission; whether regulatory
authorities will be satisfied with the design of and results from
Lucid Diagnostics' clinical and preclinical studies; whether and
when Lucid Diagnostics' products are cleared by regulatory
authorities; market acceptance of Lucid Diagnostics' products once
cleared and commercialized; Lucid Diagnostics' ability to raise
additional funding as needed; and other competitive developments.
These factors are difficult or impossible to predict accurately and
many of them are beyond Lucid Diagnostics' control. In addition,
new risks and uncertainties may arise from time to time and are
difficult to predict. For a further list and description of these
and other important risks and uncertainties that may affect Lucid
Diagnostics' future operations, see Part I, Item 1A, "Risk
Factors," in Lucid Diagnostics' most recent Annual Report on Form
10-K filed with the Securities and Exchange Commission, as the same
may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly
Report on Form 10-Q filed by Lucid Diagnostics after its most
recent Annual Report. Lucid Diagnostics disclaims any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-record-quarterly-esoguard-test-volume-302203590.html
SOURCE Lucid Diagnostics